Genomics

Dataset Information

0

Unraveling Tumor-Immune Heterogeneity in Advanced Ovarian Cancer Uncovers Immunogenic Effect of Chemotherapy [Pre&Post-Tx]


ABSTRACT: In metastatic cancer, the degree of heterogeneity of the tumor-immune microenvironment and its molecular underpinnings remain largely unstudied. To characterize the tumor-immune interface at baseline and during neoadjuvant chemotherapy in high-grade serous ovarian cancer (HGSOC), we performed immunogenomics analysis of treatment-naive and paired pre/post-chemotherapy treated samples. In treatment-naive HGSOC, we find that immune cell-excluded and inflammatory microenvironments co-exist within the same individuals and within the same tumor sites, indicating ubiquitous variability in immune cell infiltration. Analysis of tumor microenvironment cell composition, DNA copy number, mutations and gene expression showed that immune cell exclusion was associated with amplification of Myc target genes and increased expression of canonical Wnt signaling in treatment-naive HGSOC. Following neoadjuvant chemotherapy, increased natural killer cell infiltration and oligoclonal expansion of T cells were detected. We demonstrate that the tumor-immune microenvironment of advanced HGSOC is intrinsically heterogeneous and that chemotherapy induces local immune activation, suggesting that chemotherapy can potentiate the immunogenicity of immune-excluded HGSOC tumors. The goal of this particular experiment was quantify RNA expression using microarray technology, and then evaluate differences in the trasncirptomic landscape of treatment naïve metastatic high grade serous ovarian cancer.

ORGANISM(S): Homo sapiens

PROVIDER: GSE146963 | GEO | 2020/03/14

REPOSITORIES: GEO

Similar Datasets

2020-03-14 | GSE146964 | GEO
2021-12-24 | GSE165897 | GEO
2016-07-27 | E-GEOD-71340 | biostudies-arrayexpress
2021-04-20 | GSE158739 | GEO
2022-09-28 | GSE201600 | GEO
2022-09-15 | GSE213243 | GEO
2022-10-05 | PXD031929 | Pride
2024-03-15 | PXD045710 | Pride
2020-01-12 | GSE132289 | GEO
2020-05-27 | PXD014980 | Pride